LONDON — Investment linked to artificial intelligence is accelerating activity in the protein research and biotechnology sector, attracting new funding for companies that use AI to design proteins and develop medicines, while contributing to increased volatility in financial markets as investors reassess expectations for the technology’s commercial impact.
The trend has gained momentum in 2026 as venture capital firms, pharmaceutical companies and technology investors direct capital toward businesses using AI to model protein structures and accelerate drug discovery. The sector received a significant boost in May when Isomorphic Labs, a company spun out of Google DeepMind, announced it had raised $2.1 billion in a funding round aimed at expanding its AI-driven drug development platform.
Isomorphic Labs said the funding would support the scaling of its drug-design engine, which relies in part on advances derived from DeepMind’s AlphaFold technology, a system used to predict protein structures. “This capital injection allows us to build out our drug design engine at scale,” Chief Executive Demis Hassabis said in a statement announcing the investment.
The growing flow of capital into AI-related life sciences has coincided with broader investment activity across food, agriculture and biotechnology. Venture capital firm Anterra Capital said this month it had raised $100 million toward a new fund focused on food and agricultural technologies, including AI-enabled companies involved in biological and protein-related innovation. The firm said it expects the fund to grow further by the end of the year.
Industry participants say AI tools are increasingly being used to identify therapeutic targets, predict protein interactions and shorten portions of the research process. Supporters argue the technology could reduce development timelines and improve efficiency in early-stage discovery.
At the same time, investors have become more selective as spending on AI infrastructure rises and questions emerge about which companies will generate sustainable returns. Financial markets have experienced sharp swings in several AI-related stocks in recent weeks, reflecting heightened expectations and concerns about valuations. Reuters reported that shares of Broadcom fell sharply after results failed to meet some investors’ expectations regarding AI-related growth, while analysts noted broader volatility across technology sectors tied to the AI investment cycle.
Market strategists have also pointed to increasing scrutiny of AI-related capital expenditures by large technology companies. According to UBS, debate over the scale and sustainability of AI spending has contributed to heightened volatility across segments of the AI value chain.
As of June 18, investment activity in AI-driven protein research remained strong, with companies continuing to attract funding and pursue new partnerships. Investors, meanwhile, were closely monitoring whether advances in protein design and drug discovery translate into commercial results as the sector moves from research toward clinical and industrial applications.
